{"id":"W2981525398","doi":"10.1016/j.jtho.2019.08.586","title":"MA11.04 Platinum Doublet + Durvalumab +/- Tremelimumab in Patients with Advanced NSCLC: A CCTG Phase IB Study - IND.226","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Durvalumab; Internal medicine; Rash; Carboplatin; Tremelimumab; Gemcitabine; Oncology; Tolerability; Adverse effect; Pemetrexed; Nausea; Gastroenterology; Chemotherapy; Cisplatin; Nivolumab; Cancer; Ipilimumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007151469,0.0009872274,0.001885775,0.0003311867,0.0002723272,0.0008462972,0.0006993515,0.0006508792,0.003447719],"category_scores_gemma":[0.0004389328,0.0004362994,0.001349503,0.0004196231,0.0004667059,0.0006735428,0.0002564503,0.002052628,0.00138075],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001005249,"about_ca_system_score_gemma":0.001164085,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001866107,"about_ca_topic_score_gemma":0.005915666,"domain_scores_codex":[0.9997091,0.0001074252,0.000016435,0.000055965,0.00003297759,0.00007808256],"domain_scores_gemma":[0.9997275,0.00003187675,0.0000484305,0.00003763737,0.00002281109,0.0001317502],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6055011,0.04034659,0.01397338,0.001871318,0.004069983,0.0002824893,0.0001884225,0.002971521,0.03912966,0.0005225564,0.01318998,0.277953],"study_design_scores_gemma":[0.5178829,0.4223871,0.03825502,0.0001210425,0.002518038,0.0006438413,0.0001045637,0.001927465,0.00490147,0.0002832163,0.01091252,0.00006288209],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9847267,0.00646665,0.0003241199,0.0007735054,0.0002514419,0.001348201,0.002333749,0.0001384012,0.003637204],"genre_scores_gemma":[0.9782712,0.006608757,0.001123792,0.00104615,0.0003016973,0.001040836,0.005391081,0.00005398348,0.006162507],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003447719,"threshold_uncertainty_score":0.01153374,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01567304170146937,"score_gpt":0.3873143800483597,"score_spread":0.3716413383468903,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}